Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Innoviva is expected to see strong growth in the near-term due to the continued momentum of its products Giapreza and Xacduro, with solid potential for acceleration and further revenue growth in the future from upcoming guideline endorsements and new product launches. The company's reliance on royalty revenue and its successful track record in asset purchases and investments also suggest a strong foundation for future growth. Despite a recent top-line miss, Innoviva's bottom-line performance exceeded expectations due to gains from its investment portfolio, and the company's strong cash position further supports its potential for future success. Based on these factors, the outlook for Innoviva's stock appears promising for investors.

Bears say

Innoviva is facing significant challenges in generating substantial revenue, with a small increase in license and other revenue not enough to offset declines in key products like Anoro and Trelegy, while also facing negative impacts from its investment in Armata Pharmaceuticals. Additionally, while the acquisition of Lyndra Therapeutics and its proprietary LYNX drug delivery platform has potential, the company's overall financial outlook remains weak. Therefore, the future growth and success of Innoviva are uncertain, leading to a negative outlook for the stock.

Innoviva (INVA) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 4 analysts, Innoviva (INVA) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.